Display options
Cite
Dickson MA, D'Adamo DR, Keohan ML, et al. Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma. 2015;2015:532478doi: 10.1155/2015/532478.
Dickson, M. A., D'Adamo, D. R., Keohan, M. L., D'Angelo, S. P., Carvajal, R. D., Gounder, M. M., Maki, R. G., Qin, L. X., Lefkowitz, R. A., McKennon, O. R., Hirst, C. M., Schwartz, G. K., & Tap, W. D. (2015). Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma, 2015532478. https://doi.org/10.1155/2015/532478
Dickson, Mark A, et al. "Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma." Sarcoma vol. 2015 (2015): 532478. doi: https://doi.org/10.1155/2015/532478
Dickson MA, D'Adamo DR, Keohan ML, D'Angelo SP, Carvajal RD, Gounder MM, Maki RG, Qin LX, Lefkowitz RA, McKennon OR, Hirst CM, Schwartz GK, Tap WD. Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma. 2015;2015:532478. doi: 10.1155/2015/532478. Epub 2015 May 14. PMID: 26074722; PMCID: PMC4446476.
Copy Download .nbib Format: NLM
Share it on

Sarcoma. 2015;2015:532478. doi: 10.1155/2015/532478. Epub 2015 May 14.

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.

Sarcoma

Mark A Dickson, David R D'Adamo, Mary L Keohan, Sandra P D'Angelo, Richard D Carvajal, Mrinal M Gounder, Robert G Maki, Li-Xuan Qin, Robert A Lefkowitz, Olivia R McKennon, Catherine M Hirst, Gary K Schwartz, William D Tap

Affiliations

  1. Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
  2. Eisai, Inc., Woodcliff Lake, NJ, USA.
  3. Department of Medicine, Columbia University, New York, NY, USA.
  4. Departments of Medicine and Pediatrics, Mount Sinai School of Medicine, New York, NY, USA.
  5. Department of Biostatistics, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
  6. Department of Radiology, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.

PMID: 26074722 PMCID: PMC4446476 DOI: 10.1155/2015/532478

Abstract

Gemcitabine (G) and docetaxel (D) are commonly used to treat recurrent/metastatic soft tissue sarcoma. This study tested the hypothesis that outcomes would be improved by addition of bevacizumab (B). The initial design was randomized double-blind trial of G + D + B versus G + D + placebo. Due to slow accrual this was modified to single-arm open-label G + D + B. Eligible patients had diagnosis of leiomyosarcoma, pleomorphic undifferentiated sarcoma, pleomorphic liposarcoma, or angiosarcoma. Treatment was B 15 mg/kg on d1, G 900 mg/m(2) on d1 and d8, and D 75 mg/m(2) on d8, q21d. Primary endpoint was progression-free survival (PFS) at 6 months and would be met if ≥17 patients were progression-free at 6 m. Secondary endpoints are response rate, PFS at 3 m, overall survival, and toxicity. Of 44 patients enrolled, 35 were treated with GDB and evaluable for safety and efficacy. Median age was 55, 50% male, most ECOG 0. Toxicity is mostly myelosuppression with one deep vein thrombosis and one small bowel perforation possibly related to B. There were 17 partial responses (49%) by RECIST 1.1. Among 35 patients, the number who remained on study and progression-free was 24 at 3 m and 15 at 6 m. 9 withdrew prior to 6 m for reasons other than toxicity or progression. PFS at 6 m was 65% (95% CI: 51-85%). The primary endpoint of 6 m PFS was not met due to censoring of patients who withdrew. However PFS at 3 m (76%) was promising and response rate was higher than expected from G + D.

References

  1. Int J Cancer. 2006 Aug 1;119(3):706-11 - PubMed
  2. J Clin Oncol. 2005 Oct 1;23(28):7135-42 - PubMed
  3. J Clin Oncol. 2007 Jul 1;25(19):2755-63 - PubMed
  4. Gynecol Oncol. 2008 Jun;109(3):323-8 - PubMed
  5. Gynecol Oncol. 2008 Jun;109(3):329-34 - PubMed
  6. Eur J Cancer. 2002 Mar;38(4):543-9 - PubMed
  7. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  8. Ann Oncol. 2012 Mar;23(3):785-90 - PubMed
  9. Ann Oncol. 2013 Jan;24(1):257-63 - PubMed
  10. J Clin Oncol. 2002 Jun 15;20(12):2824-31 - PubMed
  11. Oncologist. 2012;17(9):1213-20 - PubMed

Publication Types

Grant support